CORD-19:775b90287b44353bee979abb0970a4666022f86d / 293231-293338 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/CORD-19/sourceid/775b90287b44353bee979abb0970a4666022f86d","sourcedb":"CORD-19","sourceid":"775b90287b44353bee979abb0970a4666022f86d","text":"The primary efficacy endpoint was baseline-adjusted FEV 1 at 30 minutes after each of the cumulative doses.","tracks":[{"project":"CORD-19-Sentences","denotations":[{"id":"T92067","span":{"begin":0,"end":107},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"attributes":[{"subj":"T92067","pred":"source","obj":"CORD-19-Sentences"}]},{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T183","span":{"begin":0,"end":107},"obj":"Sentence"}],"attributes":[{"subj":"T183","pred":"source","obj":"CORD-19_Custom_license_subset"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"CORD-19-Sentences","color":"#eca493","default":true},{"id":"CORD-19_Custom_license_subset","color":"#939bec"}]}]}}